{'fraction_non_alphanumeric': 0.043512658227848104, 'fraction_numerical': 0.03164556962025317, 'mean_word_length': 4.698198198198198, 'pattern_counts': {'":': 0, '<': 3, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
P14: HepatiC, the viral hepatitis C patients management application and database

Human/Mouse/Rat MMP-2 (total) Immunoassay twice at the beginning of therapy and 6 months after treatment. TIMP-1/MMP-2 ratio was calculated for each probe. Results were analyzed according to SVR achievement at 6 months after completion of therapy. SUMMARY OF RESULTS: In the group of 26 (48%) patients with SVR the TIMP-1/MMP-2 ratio decreased significantly after treatment (p < 0.001). In 28 (52%) patients who did not achieve SVR, the TIMP-1/MMP-2 ratio obtained after treatment was significantly higher than the values at the beginning of therapy (p < 0.05). Comparative analysis of results in groups of patients according to SVR revealed that there were no statistically significant differences in plasma TIMP-1/MMP-2 ratio at the beginning of therapy but 6 months after cessation of treatment TIMP-1/MMP-2 ratio was significantly lower in patients with a virologic response after treatment compared with no SVR group (p < 0.001). CONCLUSION: The study results showed that the balance between concentration of TIMP-1 and MMP-2 in plasma may be useful in assessing effects of antiviral treatment and predicting fibrosis in patients with CHC treated with antiviral therapy (3–12).